Claims
- 1) A compound of formula I
- 2) A compound of claim 1 wherein R1 is hydrogen, methoxy or halogen.
- 3) A compound of claim I wherein Z is NR2-(CH2)n-Y.
- 4) A compound of claim 1 wherein R2 hydrogen.
- 5) A compound of claim 1 wherein R3 is phenyl, indole, indazole, pyridine, pyrimidine, quinoline, benzoisothiazole, or benzisoxazole, each optionally substituted.
- 6) A compound of claim 1 wherein R4 is hydrogen or hydroxy.
- 7) A compound of claim 1 wherein R5 is 1 -benzimidazol-2-one, benzoisothiazole, benzisoxazole, each optionally substituted or -Q-Ar.
- 8) A compound of claim 7 wherein Q is C═O or (CH2)m.
- 9) A compound of claim 1 wherein R6 is hydrogen.
- 10) A compound of claim 1 wherein R7 is phenyl, indole, benzoisothiazole, or benzisoxazole each optionally substituted.
- 11) A compound of claim 1 wherein R6 and R7 taken together form phenyl or substituted phenyl.
- 12) A compound of claim 1 wherein R1 is hydrogen, methoxy, or halogen, Z is NR2-(CH2)n-Y and R2 is hydrogen.
- 13) A compound of claim 1 wherein Z is
- 14) A compound of claim 13 wherein R1 is hydrogen, methoxy or halogen.
- 15) A compound of claim 13 wherein Z is
- 16) A compound of claim 15 wherein R1 is hydrogen, methoxy or halogen.
- 17) A compound of claim 1 wherein Z is
- 18) A compound of claim 17 wherein R1 is hydrogen, methoxy or halogen, Q is C═O, and Ar is phenyl or substituted phenyl.
- 19) A compound of claim 1 wherein Z is
- 20) A compound of claim 19 wherein R1 is hydrogen, methoxy or halogen.
- 21) A compound of claim 1 wherein Z is
- 22) A compound of claim 21 wherein R1 is hydrogen, methoxy or halogen.
- 23) The compound of claim 1 which is 8-aminomethyl-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.
- 24) The compound of claim 1 which is 8-(benzylamino-methyl)-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.
- 25) The compound of claim 1 which is 8-[(dibenzylamino)-methyl]-7,8-dihydro- 3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.
- 26) The compound of claim 1 which is 8-[(4-phenyl-butylamino)-methyl]-7,8- dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.
- 27) The compound of claim 1 which is 8-[4-(1H-indol-3-yl)-3,6-dihydro-2H-pyridin-1 -ylmethyl]-7,8-dihydro-3H-1,6,9-trioxa-3-aza-cyclopenta[a]naphthalen-2-one or a pharmaceutically acceptable salt thereof.
- 28) A method of treating a subject suffering from a condition selected from schizophrenia, schizoaffective disorder, bipolar disorder, Parkinson's disease, L- DOPA induced psychoses or dyskinesias, Tourette's syndrome or hyperprolactinemia which comprises providing to the subject suffering from said condition, a therapeutically effective amount of a compound of formula I
- 29) The method of claim 28 wherein the subject is a human.
- 30) A pharmaceutical composition comprising a compound of formula I
Parent Case Info
[0001] This application claims priority from co-pending provisional application serial number 60/286,565, filed April 26, 2001, the entire disclosure of which is hereby incorporated by reference.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60286565 |
Apr 2001 |
US |